Arquer Diagnostics Nets Funding
The company will use the award to prepare an international clinical study to evaluate its MCM5 ELISA-based urine test for prostate cancer.
Read More
Search Results for: prostate cancer
GenomeDx, Astellas to Identify Genomic Drivers of Patient Response to Enzalutamide
The research collaboration will apply genomic tumor profiling to identify prostate cancer patients undergoing active surveillance who may benefit from treatment with enzalutamide.
Read MoreProlaris Gets Favorable Final Local Coverage Decision
Noridian has issued a positive LCD for the Prolaris prostate cancer test by Myriad Genetics.
Read MoreRosetta Genomics Receives Notice of Allowance for US Patent
The US Patent and Trademark Office has issued a notice of allowance to Rosetta Genomics for its patent application covering compositions and methods for prognosis and treatment of prostate cancer.
Read MoreMyriad Publishes Clinical Utility Study for Prolaris
Data from the Procede 500 study of cell-cycle progression testing with the Prolaris RNA-expression test indicate that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the test.
Read More